Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy

Table 4 Multivariate regression analysis for ∆ FABP4

	Regression coefficient	SE	Standardized regression coefficient (β)	P
Age	0.01	0.07	0.01	0.91
Sex (male)	− 1.82	1.30	− 0.07	0.16
DPP-4i (anagliptin)	− 1.81	1.23	− 0.07	0.14
FABP4 at baseline	− 0.31	0.03	− 0.45	< 0.01
∆ Waist circumference	0.29	0.14	0.10	0.04
∆ Creatinine	26.1	5.27	0.25	< 0.01

R² = 0.294
∆, change calculated as parameter in 52 weeks minus that in baseline
DPP-4i dipeptidyl peptidase-4 inhibitor, eGFR estimated glomerular filtration rate, FABP4 fatty acid-binding protein 4

ISSN: 1475-2840